FNY Managed Accounts’s Krystal Biotech KRYS Stock Holding History

FNY Managed Accounts’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,400	Closed	-$23K	–	745
2017 Q3	$23K	Buy	+2,400	New	+$24.2K	0.03%	316

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FNY Managed Accounts's KRYS Position: Q4 2017 in Review

FNY Managed Accounts sold out of Krystal Biotech (KRYS) in Q4 2017, closing a stake of 2,400 shares — an estimated $23K sold.

FNY Managed Accounts first reported a position in KRYS in Q3 2017 and held it in 1 quarter. The position peaked at $23K in Q3 2017. 13 funds tracked by Wall St. Rank hold KRYS as of Q4 2017.

FNY Managed Accounts reported no remaining Krystal Biotech position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 2,400 Krystal Biotech shares in Q4 2017, an estimated $23K.
FNY Managed Accounts first reported a position in Krystal Biotech in Q3 2017 and held it in 1 quarter.
FNY Managed Accounts's Krystal Biotech position peaked at $23K in Q3 2017.
13 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.